Investigational drug · Phase 2
IDP-023
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for NHL, Multiple Myeloma, Blood Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 3, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "IDP-023"
First trial start
2023
Oct 25, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IDP-023", any sponsor or status.
Conditions studied
As listed on its trial records.
- NHL
- Multiple Myeloma
- Blood Cancer
- Refractory Non-Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "IDP-023" as an intervention, largest first.
Indapta Therapeutics, INC.Industry
NCT06119685 · 128 participants (planned) · Start Oct 25, 2023 · Primary completion Dec 30, 2025
Drug: IDP-023; Rituximab and 6 more · For: NHL; Multiple Myeloma; Blood Cancer and 4 more
Sites: Los Angeles, California; Lake Mary, Florida; Atlanta, Georgia · 12 sites in all
Indapta Therapeutics, INC.Industry
NCT06677710 · 34 participants (planned) · Start Jun 30, 2026 · Primary completion Dec 31, 2026
Drug: IDP-023; Ocrelizumab and 4 more · For: Multiple Sclerosis; Primary Progressive Multiple Sclerosis (PPMS); Secondary Progressive Multiple Sclerosis (SPMS) and 8 more
Sites: Stanford, California; Aurora, Colorado; Orlando, Florida · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.